181 related articles for article (PubMed ID: 11384681)
1. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.
Yazaki PJ; Shively L; Clark C; Cheung CW; Le W; Szpikowska B; Shively JE; Raubitschek AA; Wu AM
J Immunol Methods; 2001 Jul; 253(1-2):195-208. PubMed ID: 11384681
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA
Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683
[TBL] [Abstract][Full Text] [Related]
3. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
Hu S; Shively L; Raubitschek A; Sherman M; Williams LE; Wong JY; Shively JE; Wu AM
Cancer Res; 1996 Jul; 56(13):3055-61. PubMed ID: 8674062
[TBL] [Abstract][Full Text] [Related]
4. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
[TBL] [Abstract][Full Text] [Related]
5. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
6. Production of a single chain anti-CEA antibody from the hybridoma cell line T84.66 using a modified colony-lift selection procedure to detect antigen-positive ScFv bacterial clones.
Rodenburg CM; Mernaugh R; Bilbao G; Khazaeli MB
Hybridoma; 1998 Feb; 17(1):1-8. PubMed ID: 9523232
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.
Carmichael JA; Power BE; Garrett TP; Yazaki PJ; Shively JE; Raubischek AA; Wu AM; Hudson PJ
J Mol Biol; 2003 Feb; 326(2):341-51. PubMed ID: 12559905
[TBL] [Abstract][Full Text] [Related]
8. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
[TBL] [Abstract][Full Text] [Related]
9. Production of antibody fragments in a bioreactor.
Hellebust H
Methods Mol Biol; 2003; 207():437-41. PubMed ID: 12412490
[No Abstract] [Full Text] [Related]
10. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
11. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
Wu AM; Yazaki PJ; Tsai Sw; Nguyen K; Anderson AL; McCarthy DW; Welch MJ; Shively JE; Williams LE; Raubitschek AA; Wong JY; Toyokuni T; Phelps ME; Gambhir SS
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8495-500. PubMed ID: 10880576
[TBL] [Abstract][Full Text] [Related]
12. Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Yazaki PJ; Sherman MA; Shively JE; Ikle D; Williams LE; Wong JY; Colcher D; Wu AM; Raubitschek AA
Protein Eng Des Sel; 2004 May; 17(5):481-9. PubMed ID: 15316127
[TBL] [Abstract][Full Text] [Related]
13. A carcinoembryonic antigen-specific diabody produced in tobacco.
Vaquero C; Sack M; Schuster F; Finnern R; Drossard J; Schumann D; Reimann A; Fischer R
FASEB J; 2002 Mar; 16(3):408-10. PubMed ID: 11790722
[TBL] [Abstract][Full Text] [Related]
14. Production, purification and characterization of an anti-(carcinoembryonic antigen) recombinant single-chain Fv antibody fragment.
Pérez L; Vázquez JE; Ayala M; Siccardi AG; Tresoldi E; de Lalla C; Gavilondo JV; Sidoli A
Biotechnol Appl Biochem; 1996 Aug; 24(1):79-82. PubMed ID: 8756397
[TBL] [Abstract][Full Text] [Related]
15. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
Olafsen T; Kenanova VE; Sundaresan G; Anderson AL; Crow D; Yazaki PJ; Li L; Press MF; Gambhir SS; Williams LE; Wong JY; Raubitschek AA; Shively JE; Wu AM
Cancer Res; 2005 Jul; 65(13):5907-16. PubMed ID: 15994969
[TBL] [Abstract][Full Text] [Related]
16. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
17. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
